FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W958902130> ?p ?o ?g. }

• W958902130 abstract "OBJECTIVE:To evaluate the impact of female sex and fertile age on prevalence, clinical features and response to attack treatment in patients with NMO and its spectrum disorders (NMOSD). BACKGROUND: Gender and age at onset are important epidemiological factors influencing prevalence, clinical presentation and treatment response in autoimmune diseases. Until now, only little is known about the effects of gender and reproductive age in NMO. DESIGN/METHODS: Patient records in the database of the Neuromyelitis Optica Study Group were reviewed retrospectively. Demographic characteristics, diagnosis at last follow-up, details of the various NMO attacks, relapse treatment and attack outcome were compared according to sex and periods of life. RESULTS: 186 NMO and NMOSD patients (82[percnt] female) were included. Male to female ratio was 1:8 in patients aged 15 to 40 years at disease onset, and 1:3 in patients >40 years (p<0.05). Interval between onset and diagnosis was longer in women than in men (mean 54 vs. 27 months; p<0.05). Females were more likely to be positive for aquaporin-4-antibodies (92 vs. 55[percnt]; p<0.001). Gender had no effects on remission and treatment outcomes of NMO attacks.Females >40 years at disease onset were less likely to develop optic neuritis (p 40 years at onset (all p≤0.001). CONCLUSIONS: Our data suggest an influence of gender on NMO susceptibility and antibody status. Female predominance is pronounced during fertile age. At least in part, clinical presentation and response to relapse treatment in women depend on whether disease started during fertile age or later. Thus, genetic and hormonal factors are considered to be involved in disease pathophysiology. Disclosure: Dr. Borisow has nothing to disclose. Dr. Kleiter has received personal compensation for activities with Bayer Pharmaceuticals Corp., Biogen Idec, Merck Serono, and Novartis. Dr. Kleiter has received research support from Bayer Pharmaceuticals Corp., and Novartis. Dr. Trebst has nothing to disclose. Dr. Gahlen has nothing to disclose. Dr. Fischer has nothing to disclose. Dr. Jarius has received research support from Bayer Healthcare and Merck Serono. Dr. Paul has received personal compensation for activities with Teva Neuroscience, Sanofi-Aventis Pharmaceuticals, Bayer Schering Pharma, Merck Serono, Biogen Idec, MedImmune, and Novartis., Dr. Hellwig has received personal compensation for activities with Bayer Schering, Biogen Idec, Merck Serono, Teva, Aventis Pharmaceuticals , and Novartis. Dr. Hellwig has received research support from the German Research Foundation." @default.
• W958902130 created "2016-06-24" @default.
• W958902130 creator A5008016806 @default.
• W958902130 creator A5008942652 @default.
• W958902130 creator A5024839475 @default.
• W958902130 creator A5043996334 @default.
• W958902130 creator A5050382898 @default.
• W958902130 creator A5056912783 @default.
• W958902130 creator A5061733690 @default.
• W958902130 creator A5081462122 @default.
• W958902130 date "2015-04-06" @default.
• W958902130 modified "2023-10-01" @default.
• W958902130 title "Influence of Female Sex and Fertile Age on Neuromyelitis Optica (NMO) (P5.251)" @default.
• W958902130 hasPublicationYear "2015" @default.
• W958902130 type Work @default.
• W958902130 sameAs 958902130 @default.
• W958902130 citedByCount "0" @default.
• W958902130 crossrefType "journal-article" @default.
• W958902130 hasAuthorship W958902130A5008016806 @default.
• W958902130 hasAuthorship W958902130A5008942652 @default.
• W958902130 hasAuthorship W958902130A5024839475 @default.
• W958902130 hasAuthorship W958902130A5043996334 @default.
• W958902130 hasAuthorship W958902130A5050382898 @default.
• W958902130 hasAuthorship W958902130A5056912783 @default.
• W958902130 hasAuthorship W958902130A5061733690 @default.
• W958902130 hasAuthorship W958902130A5081462122 @default.
• W958902130 hasConcept C107130276 @default.
• W958902130 hasConcept C126322002 @default.
• W958902130 hasConcept C187212893 @default.
• W958902130 hasConcept C203014093 @default.
• W958902130 hasConcept C2776572573 @default.
• W958902130 hasConcept C2777767895 @default.
• W958902130 hasConcept C2779134260 @default.
• W958902130 hasConcept C2780640218 @default.
• W958902130 hasConcept C2781137167 @default.
• W958902130 hasConcept C71924100 @default.
• W958902130 hasConceptScore W958902130C107130276 @default.
• W958902130 hasConceptScore W958902130C126322002 @default.
• W958902130 hasConceptScore W958902130C187212893 @default.
• W958902130 hasConceptScore W958902130C203014093 @default.
• W958902130 hasConceptScore W958902130C2776572573 @default.
• W958902130 hasConceptScore W958902130C2777767895 @default.
• W958902130 hasConceptScore W958902130C2779134260 @default.
• W958902130 hasConceptScore W958902130C2780640218 @default.
• W958902130 hasConceptScore W958902130C2781137167 @default.
• W958902130 hasConceptScore W958902130C71924100 @default.
• W958902130 hasLocation W9589021301 @default.
• W958902130 hasOpenAccess W958902130 @default.
• W958902130 hasPrimaryLocation W9589021301 @default.
• W958902130 hasVolume "84" @default.
• W958902130 isParatext "false" @default.
• W958902130 isRetracted "false" @default.
• W958902130 magId "958902130" @default.
• W958902130 workType "article" @default.